Are there antibody-drug conjugates approved for Hairy Cell Leukemia

Antibody-Drug Conjugates for Hairy Cell Leukemia

Based on the current NCCN Guidelines for Hairy Cell Leukemia (Version 1.2026), there is one antibody-drug conjugate that has been studied and used for HCL: moxetumomab pasudotox.

What is Moxetumomab Pasudotox?

Moxetumomab pasudotox is an immunotoxin (a type of antibody-drug conjugate) that targets CD22, a protein found on hairy cell leukemia cells. The antibody portion recognizes and binds to CD22, while the drug portion (a toxin) is delivered directly into the cancer cells to kill them.

Clinical Use in HCL

According to the NCCN Guidelines, moxetumomab pasudotox has been evaluated for:

• Relapsed/refractory hairy cell leukemia (HCL that has returned after initial treatment or didn't respond to first-line therapy)
• Patients who have been heavily pre-treated with multiple prior therapies

The guidelines reference studies showing its effectiveness in this heavily treated patient population, with long-term follow-up data available from pivotal trials.

Current Treatment Landscape

However, it's important to note that moxetumomab pasudotox is not listed as a preferred or commonly recommended first-line option in the current NCCN Guidelines. The preferred initial treatments for HCL remain:

• Purine analogs (cladribine or pentostatin), with or without rituximab
• BRAF inhibitors (vemurafenib or dabrafenib/trametinib) for BRAF V600E-positive disease

For relapsed/refractory disease, other options like BRAF inhibitors, venetoclax, zanubrutinib, and ibrutinib are now more commonly used.

Questions to Ask Your Oncologist

If you're interested in antibody-drug conjugate options:

1. Is moxetumomab pasudotox appropriate for my specific situation? (considering your prior treatments and disease status)
2. Are there clinical trials available that include antibody-drug conjugates?
3. What are the side effects and monitoring requirements if this treatment is considered?
4. How does this compare to other relapsed/refractory options available to me?
5. What is the expected response rate and duration of response with this approach?

According to the NCCN Guidelines, clinical trials should always be considered as an option, particularly for relapsed or refractory disease where newer approaches may be available.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.